The worldwide prevalence of type 1 diabetes motivates the development of different treatment options for the disease. Current clinical treatments typically require patient involvement, often resulting in stress or inconvenience to the patient due to frequent blood glucose measurements and insulin injections or infusions. Islet transplantation, a potentially curative treatment, is limited by donor availability and the need for long-term administration of immunosuppressants. Cell encapsulation may prevent graft rejection without immunosuppression, however, foreign body responses, mass transfer limitations, scalability, and safety are all significant challenges. This Spotlight paper summarizes our recent efforts to address these challenges including developing biomaterials to mitigate foreign body responses and fibrosis, engineering scalable and retrievable encapsulation devices, as well as designing oxygen supplementation and vascularization strategies.

中文翻译：

---

胰岛封装和移植中的生物材料应用

1 型糖尿病在世界范围内的流行推动了针对该疾病的不同治疗方案的开发。当前的临床治疗通常需要患者参与，由于频繁的血糖测量和胰岛素注射或输注，通常会给患者带来压力或不便。胰岛移植是一种潜在的治愈性治疗方法，但受到供体可用性和长期使用免疫抑制剂的限制。细胞封装可以在没有免疫抑制的情况下防止移植排斥，但是，异物反应、传质限制、可扩展性和安全性都是重大挑战。这篇 Spotlight 论文总结了我们最近为应对这些挑战所做的努力，包括开发生物材料以减轻异物反应和纤维化，